NuCana

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738. 18 October 2025 -- Berlin, Germany -- NuCana presented data at the European Society for Medical Oncology Congress 2025 (ESMO) on a new model system investigating the synergistic effects of NUC-7738 and...

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumour Biology in a Paired Biopsy Clinical Study

NUC-7738 reprogrammes cancer cell lipid metabolism to make tumours less aggressive and promote cancer cell death NUC-7738 alters ribosome biogenesis and the regulation of genes critical for cancer growth and survival 9 April 2024 -- California, US -- NuCana announced two posters being presented today at the American Association of Cancer Research (AACR) Annual Meeting....
https://www.nucana.com/

https://www.nucana.com/